Answers are grounded in this paper and cite their sources.
Gastroesophageal reflux disease (GERD) continues to be a common problem in pediatrics. Even though multiple agents have been suggested as effective for treatment, a paucity of comparative studies prevents the determination of which is the best therapy. In recent years, cisapride has emerged as one of the first line prokinetic drugs for use in the treatment of GERD. Cisapride has been prescribed to more than 140 million patients, has been shown in placebo-controlled trials to reduce GER, and is still considered in many centers as the first choice for treatment of children in whom medication is indicated. Other effective medications, such as the proton pump inhibitors, are usually reserved for children with more severe disease that has not responded to initial therapy. Controversy regarding the safety of using cisapride in infants, children, and adolescents erupted recently when reports of adverse cardiac events started to appear, culminating in the announcement by Janssen Pharmaceutica during the summer of 1998 that the labelling of cisapride has been changed to reflect the possibility of these occurrences. This decision precipitated a series of events that could have profound influence on the clinical practice of pediatric gastroenterology, particularly in the management of GERD. Parents of children being treated with or offered cisapride as therapy, as well as physicians who prescribe it and pharmacists who dispense it are now thoroughly confused about the drug. Even though there is clear evidence of the effectiveness of prokinetics in the treatment of GERD, and that cisapride is more effective than the other medications used in the first line of treatment, there has been increasing reluctance to use it in children. The decision to prescribe cisapride must take into account the risk/benefit ratio, carefully considering evidence of effectiveness of the drug and comparing this with known and potential risks and the availability of effective alternatives. A decision based on a scientific approach is most desirable; nevertheless, other influences including medical standards of care, paucity of information, a physician's own clinical experience, existing warnings, and patient and family circumstances undoubtedly have a modifying influence. To assist the practicing pediatric gastroenterologist in making an informed decision, some new perspective are needed to help clarify the confusion that has been created. ESPGHN and NASPGN have mounted a rapid response by issuing official statements on the use of cisapride in children (J Pediatr Gastroenterol Nutr 1999;28:518-528 andJ Pediatr Gastroenterol Nutr 1999;28:529-533 ). Both societies have undertaken an extensive review of the literature and conclude that cisapride continues to be an effective and safe treatment for children with GERD. Suggestions and recommendations on how to use the drug, and what precautions, if any, need to be taken are provided. These papers are a welcome addition to the literature, as they provide an authoritative support for the continued use of a medication that has been proven effective in the initial treatment of children with GERD and other conditions. Current recommendations indicate that when use of the medication is necessary, cisapride can be employed at a dose of 0.8 mg/kg/d, without exceeding the recommended adult dose of 20 mg QID. Most importantly, cisapride should not be used in conjunction with medications known to prolong the QTc interval, when there are known abnormalities of the QTc, and when there are serum electrolyte abnormalities. The drug should be used with caution in premature babies and in patients with renal, cardiac, or liver disease. There is at present no evidence to suggest that all patients begun on cisapride and who have no other risk factors need an electrocardiogram before initiation of treatment. However, it is conceivable that identification of significant QTc interval prolongation in those children already taking cisapride would lead to discontinuation of the drug (J Pediatr Gastroenterol Nutr 1999;28:529-533 ). Studies are now required to establish which patients need an electrocardiogram and how often follow-up is needed. For now, individual pediatric gastroenterologists will have to decide which patients need this type of evaluation. The complex events surrounding the cisapride controversy exemplify the new world in which we live. The speed at which information travels and becomes available to the general public, sometimes without a clear presentation of the necessary perspectives and varying viewpoints, can have a profound influence on the way clinical medicine is practiced. At times this leaves the individual patient and physician without adequate resources to make an informed decision. Importantly, this conundrum illustrates the role and influence that our representative societies can have and the need to provide a rapid and evidence-based response to place complex issues in perspective. The use of an evidence-based approach for the treatment of children is preferred. Accordingly, we should resist the impulse of letting anecdotal experience and unsubstantiated fear dictate the way pediatric gastroenterology is practiced. Samuel Nurko, MD Children's Hospital, Combined Program in Pediatric Gastroenterology and Nutrition, Harvard Medical School, Boston, Massachusetts, U.S.A.
No takes yet. Share an insight, caveat, or question.
Samuel Nurko (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: